Moderna Inc

Moderna Inc- Financial and Strategic Analysis Review

Company Overview
Moderna Inc (Moderna) operates as a developer of messenger RNA therapeutics. The
company develops and discovers drugs that produce proteins or antibodies inside patient
cells. Its pipeline includes various drug modalities such as prophylactic vaccines, therapeutic
vaccines, intratumoral immuno-oncology, localized therapeutics, and liver intracellular.
Moderna through its mRNA therapeutics platform develops and produces human proteins,
antibodies, and novel proteins, which help in preventing, treating, and curing diseases. It also
develops therapeutics in the areas of infectious disease, rare liver disease, immuno-oncology,
and cardiovascular disease. Moderna Therapeutics is headquartered in Cambridge,
Massachusetts, the US.
The company reported revenues of (US Dollars) US$19,263 million for the fiscal year ended
December 2022 (FY2022), an increase of 4.3% over FY2021. In FY2022, the company’s
operating margin was 48.9%, compared to an operating margin of 72% in FY2021. In
FY2022, the company recorded a net margin of 43.4%, compared to a net margin of 66.1% in
FY2021.

Moderna Inc - Key Facts

Moderna Inc, Key Facts
Corporate Address 200 Technology Sq, Ticker Symbol, MRNA [NASD]
Cambridge, Exchange
02139-3578,
United States of
America.
Telephone 1 617 7146500 No. of Employees 2,700
Fax 1 617 5831998 Fiscal Year End December
URL www.modernatx.com Revenue (in US$ 19,263
Million)
Source : MarketLine Research analysis / © MarketLine Research

Disclaimer:

All Rights Reserved.

This information has been extracted from MarketLine by a registered user

No part of this publication may be reproduced, stored in a retrieval system or

transmitted in any form by any means, electronic, mechanical, photocopying,
recording or otherwise, without the prior permission of the publisher, MarketLine.

The facts of this report are believed to be correct at the time of publication but cannot
be guaranteed. Please note that the findings, conclusions and recommendations that
MarketLine delivers will be based on information gathered in good faith from both
primary and secondary sources, whose accuracy we are not always in a position to
guarantee. As such MarketLine can accept no liability whatever for actions taken
based on any information that may subsequently prove to be incorrect.

Published: 01 Mar 2023 Page 1

Extracted: 12 Mar 2023